CN1153168A - Elemene hydroxyls derivs. and their use as anticancer drugs - Google Patents
Elemene hydroxyls derivs. and their use as anticancer drugs Download PDFInfo
- Publication number
- CN1153168A CN1153168A CN 95114026 CN95114026A CN1153168A CN 1153168 A CN1153168 A CN 1153168A CN 95114026 CN95114026 CN 95114026 CN 95114026 A CN95114026 A CN 95114026A CN 1153168 A CN1153168 A CN 1153168A
- Authority
- CN
- China
- Prior art keywords
- elemenum
- amido
- functional group
- reaction
- elemene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An hydroxyl derivatives of elemene are prepared through the reaction of elemene with hypochlorite to obtain intermediates and the reaction of said intermediates with hydroxyl functional group-containing compound. Said derivatives can be used as anticancer medicine with anticancer activity higher than that of elemene.
Description
The present invention relates to a kind of organic compound, elemene hydroxyls derivs, and the synthetic method of this derivative is provided and has been used as cancer therapy drug.
In the research of cancer therapy drug, once to report nitrogenous alkaloids and terpene compound and had antitumous effect, the sesquiterpene compounds Elemenum that China newly develops is exactly wherein a kind of.Elemenum is a kind of Chinese medicine cancer therapy drug of China, and its molecule is C
15H
24, structural formula is as (1):
Elemenum now has been used for clinical as Chinese medicine, but how its water-soluble extreme difference further improves its antitumous effect, is still waiting research.
The purpose of this invention is to provide a kind of elemene hydroxyls derivs, the method for synthetic this derivative is provided simultaneously.Another object of the present invention be with elemene hydroxyls derivs as medicine, the smelting that is applied to cancer is treated.
Elemene hydroxyls derivs of the present invention is characterized in that molecular formula is C
15H
22R
1R
2Structural formula is (2):
Wherein be 1) R
1Be H, R
2Be amido di-alcohol or amido oxalic acid; 2) R
2Be H, R
1Be amido di-alcohol or amido oxalic acid or 3) R
1=R
2Be amido di-alcohol or amido oxalic acid.
The building-up process of elemene hydroxyls derivs of the present invention is by following step:
1. Elemenum carries out chlorination reaction with hypochlorite and obtains Elemenum chloro thing intermediate product;
2. get the Elemenum derivative of corresponding hydroxyl with the molecular reaction of intermediate product and hydroxyl functional group.The reactant of so-called hydroxyl functional group is diethanolamine or diethyl acid amide.
Used hypochlorite can be used clorox in the above-mentioned steps 1, potassium or calcium salt, and also available chlorinated lime or bleaching are smart.The mol ratio of the consumption of hypochlorite (or available chlorine content) and Elemenum is 1.0～3.0, and reaction adds entry or organic solvent, and organic solvent is a chlorinated hydrocarbon, as chlorine spin, methylene dichloride, monochloroethane or ethylene dichloride; The volume ratio of organic solvent and water is 3～5, and the add-on of organic solvent is heavy 2～10 times of Elemenum, and the organic solvent add-on is very few, is unfavorable for that reaction carries out, and too much makes the reaction unfavorable separation in back again.Be reflected under normal temperature, the normal pressure and carry out.In the step 2, available step 1 is made the intermediate product Elemenum chloro thing of purification, also step 1 can be carried out the reaction that mixture after the chlorination reaction is directly used in step 2.The mol ratio of reactant diethanolamine or diethyl acid amide and Elemenum molecule is 1～5.Synthesize in the solvent of methyl alcohol, ethanol, propyl alcohol, methyl ether or ether, adopt widely different stream reaction carrying out finishing in 1～15 hour reaction.After reaction mixture concentrates, carry out polarity through silica gel column chromatography successively with sherwood oil and solvent and wash towards obtaining product.
Elemene hydroxyls derivs provided by the present invention can be used as cancer therapy drug and uses, its anti-tumor in vivo test performance positive effect.
Below by embodiment technology of the present invention is given to illustrate further.
The preparation of embodiment 1. beta-elemene chloro thing intermediates
In the 500ml four-necked bottle of agitator reflux exchanger is housed, add 20.4 gram beta-elemenes, 300ml methylene dichloride and 80ml water feed CO
2Stir to add in 4 hours down in batches and bleach essence (containing Losantin 34%) totally 20 grams, half an hour, suction filtration are then reacted in the reinforced back continuation that finishes, filtrate is told organic phase, with 4 * 20ml dichloromethane extraction water, merge organic phase, add anhydrous magnesium sulfate drying and spend the night, steaming desolventizes, get yellow oil, separate through silicagel column, the sherwood oil wash-out gets 10.2 gram β Elemenum muriates.
The preparation of embodiment 2. beta-elemene ethanolamine derivatives
The mixture (chloride 45%) of 29 gram beta-elemenes and the chloro things that example 1 is obtained, with 11 gram diethanolamine, 0.82 gram potassiumiodide back flow reaction 8 hours in the 40ml dehydrated alcohol.Boil off solvent, get yellow viscous fluid.Through silica gel column chromatography, sherwood oil washes by unreacted reactant, and ether washes out product solution, draws beta-elemene ethanolamine derivative 10.5 grams at last.
The test of embodiment 3. anti-tumor in vivo
Laboratory animal L
615Purebred mouse is provided by Dalian Medical Univ's Experimental Animal Center, rat liver cancer ascitic type (H
22) the knurl strain draws from institute of Materia Medica,Chinese Academy of Medical Sciences tumour chamber, is inoculated in the growth of going down to posterity in the kunming mice chamber.Beta-elemene and ethanolamine derivative controlled trial thereof, with 1% tween-80 physiological saline solution, and ultrasonic hydrotropy.Medicine is once tested used L to the inhibition test of transplanted tumor
615Mouse is same sex or male and female half and half, with the H of inoculation
22Kunming mice ascites, with after the sterile saline dilution, be seeded in L
615Mouse armpit is subcutaneous.Grouping and intraperitoneal injection of drugs behind the inoculation 24h, administration volume are that per 10 gram body weight add 20ml, every day 1 time, and record administration fate, the mouse body weight, the number of animals that the experiment beginning comes is observed mouse feed and generalized case.Time constraint medicine is not after 24 days, put to death whole mouse and peel off lump, weigh, calculating tumour inhibiting rate (the average knurl of the average knurl weight/control animals of 1-administration animal is heavy) * 100% data analysis is that all experimental datas are earlier after Bartlett method check homoscedasticity, carry out variance analysis at random or approximating variances analysis again, the meaningful person of difference adopts the statistical significance of difference between q Rough Inspection method analysis bank.
The anti-tumor in vivo effect of medicine sees the following form: the heavy tumour inhibiting rate P of drug dose route of administration number of animals body weight g knurl value
Mg/Kg and number of times begin to begin at last to finish g % contrast (1% iP * 10 12 12 23.2 22.6 1.06 ± 0.71 tween physiological saline) diethanolamine 100 iP * 10 12 12 22.9 19.7 0.52 ± 0.26 51＜0.01 derivative 80 iP * 10 12 10 23.7 20.8 0.52 ± 0.18 51＜0.01
60 iP * 10 12 12 23.0 21.5 0.80 ± 0.31 25 beta-elemene, 50 ip * 10 12 12 23.8 22.1 0.55 ± 0.19 48＜0.01
Its three revision tests, it is to H
22Tumour inhibiting rate is basic identical.The anti-tumor in vivo test-results shows that the ethanolamine derivant of beta-elemene is to L
815The H of mouse inoculation
22Solid tumor has significantly reliable dose-dependent restraining effect.
By above-mentioned example, elemene hydroxyls derivs of the present invention can improve the water-soluble of Elemenum simultaneously except the antitumour activity of doing well, improve its anticancer effect.In addition, the simple synthetic method of elemene hydroxyls derivs provided by the invention, reaction conditions and easy to control is easy to realize suitability for industrialized production.
Claims (5)
1. Elemenum hydroxy derivatives is characterized in that and can be represented by molecular structural formula down:
Wherein be 1) R
1Be H, R
2Be amido di-alcohol or amido oxalic acid; 2) R
2Be H, R
1Be amido di-alcohol or amido oxalic acid or 3) R
1=R
2Be amido di-alcohol or amido oxalic acid.
2. preparation method of Elemenum hydroxy derivatives according to claim 1 is characterized in that pressing step:
1) Elemenum carries out chlorination reaction with hypochlorite and obtains Elemenum muriate intermediate product;
2) molecular reaction with intermediate product and hydroxyl functional group obtains containing corresponding hydroxy derivative, and the reactant of so-called hydroxyl functional group is diethanolamine or diethyl acid amide.
3. according to the described preparation method of claim 2, it is characterized in that the used hypochlorite of step 1 is clorox, potassium or calcium salt, chlorinated lime or bleaching are smart, and the consumption of hypochlorite and the mol ratio of Elemenum are 1.0～3.0.
4. according to the described preparation method of claim 2, it is characterized in that step 2 makes the intermediate product of purification or step 1 is carried out the molecular reaction that mixture after the chlorination reaction is directly used in step 2 and hydroxyl functional group with step 1, the molecule of reactant hydroxyl functional group and the mol ratio of Elemenum molecule are 1～5.
5. the application of Elemenum hydroxy derivatives according to claim 1 is characterized in that as cancer therapy drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95114026A CN1052716C (en) | 1995-12-26 | 1995-12-26 | Elemene hydroxyls derivs. and their use as anticancer drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95114026A CN1052716C (en) | 1995-12-26 | 1995-12-26 | Elemene hydroxyls derivs. and their use as anticancer drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1153168A true CN1153168A (en) | 1997-07-02 |
| CN1052716C CN1052716C (en) | 2000-05-24 |
Family
ID=5080219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN95114026A Expired - Fee Related CN1052716C (en) | 1995-12-26 | 1995-12-26 | Elemene hydroxyls derivs. and their use as anticancer drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1052716C (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1318405C (en) * | 2004-08-20 | 2007-05-30 | 中国科学院大连化学物理研究所 | Azo heterocycle beta-elemene piperazine alkyl derivative and its preparation and uses |
| CN1318408C (en) * | 2004-08-20 | 2007-05-30 | 中国科学院大连化学物理研究所 | Azo hetercyle beta-elemene derivative and its preparation method and uses |
| CN100528824C (en) * | 2006-10-18 | 2009-08-19 | 中国科学院上海应用物理研究所 | Beta-elemene monosubstituted ether derivatives, synthesis method and use thereof |
| CN101161290B (en) * | 2006-10-11 | 2010-12-01 | 中国科学院上海应用物理研究所 | Beta-elemi alkene polyglycol amine derivant as well as its synthesis method and purpose |
| CN101225049B (en) * | 2006-10-20 | 2011-06-01 | 中国科学院上海应用物理研究所 | Beta-elemene amino acid derivatives as well as synthetic method and use thereof |
| CN1850779B (en) * | 2006-05-10 | 2012-08-29 | 沈阳药科大学 | Beta-element nitrogenous derivative, and its preparing method and use |
| CN116143661A (en) * | 2022-02-28 | 2023-05-23 | 杭州师范大学 | Beta-elemene asymmetric substituted derivative and its preparation and use |
| WO2023160039A1 (en) * | 2022-02-28 | 2023-08-31 | 杭州师范大学 | β-ELEMENE DERIVATIVE WITH HDACI PHARMACOPHORE, AND PREPARATION METHOD THEREFOR AND USE THEREOF |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1060038C (en) * | 1993-02-15 | 2001-01-03 | 大连市医药科学研究所 | Elemene emulsion injection and its preparing process |
-
1995
- 1995-12-26 CN CN95114026A patent/CN1052716C/en not_active Expired - Fee Related
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1318405C (en) * | 2004-08-20 | 2007-05-30 | 中国科学院大连化学物理研究所 | Azo heterocycle beta-elemene piperazine alkyl derivative and its preparation and uses |
| CN1318408C (en) * | 2004-08-20 | 2007-05-30 | 中国科学院大连化学物理研究所 | Azo hetercyle beta-elemene derivative and its preparation method and uses |
| CN1850779B (en) * | 2006-05-10 | 2012-08-29 | 沈阳药科大学 | Beta-element nitrogenous derivative, and its preparing method and use |
| CN101161290B (en) * | 2006-10-11 | 2010-12-01 | 中国科学院上海应用物理研究所 | Beta-elemi alkene polyglycol amine derivant as well as its synthesis method and purpose |
| CN100528824C (en) * | 2006-10-18 | 2009-08-19 | 中国科学院上海应用物理研究所 | Beta-elemene monosubstituted ether derivatives, synthesis method and use thereof |
| CN101225049B (en) * | 2006-10-20 | 2011-06-01 | 中国科学院上海应用物理研究所 | Beta-elemene amino acid derivatives as well as synthetic method and use thereof |
| CN116143661A (en) * | 2022-02-28 | 2023-05-23 | 杭州师范大学 | Beta-elemene asymmetric substituted derivative and its preparation and use |
| WO2023160039A1 (en) * | 2022-02-28 | 2023-08-31 | 杭州师范大学 | β-ELEMENE DERIVATIVE WITH HDACI PHARMACOPHORE, AND PREPARATION METHOD THEREFOR AND USE THEREOF |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1052716C (en) | 2000-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2233716C (en) | Methods of using discodermolide compounds | |
| CN1052716C (en) | Elemene hydroxyls derivs. and their use as anticancer drugs | |
| CN111529716A (en) | Polypeptide-paclitaxel conjugate and application thereof | |
| CN106631957B (en) | A kind of antitumoral compounds and the preparation method and application thereof targeting FAP-alpha enzyme | |
| CN105408351A (en) | Peptide for suppressing osteoclast differentiation and use thereof | |
| CN108484536B (en) | Synthetic method of orlistat intermediate of weight-reducing drug | |
| US20080089924A1 (en) | Multimeric Oleamide Derivative Having Connexin-26 Inhibiting Potency and Use Thereof in Cancer Therapy, etc. | |
| CN110452098A (en) | Quaterphenyl aromatic hydrocarbons, its water soluble sulfonated object and the preparation method that full hydroxyl replaces | |
| CN113956266A (en) | Method for synthesizing tetrodotoxin on large scale | |
| CN1273496C (en) | Polysaccharose MF4 of mussel with enhancing immunity and anti-tumour activity | |
| CN114805269B (en) | Eriocalyxin B derivative and application thereof in preparation of antitumor drugs | |
| EP2231695B1 (en) | Antitumoral compounds | |
| CN108752404B (en) | A kind of berberine salt derivative and its preparation method and application that triazole is sugar-modified | |
| CN101456824A (en) | Alpha-amido-N-substituted amide compounds, medicament composition containing the same and use thereof | |
| WO2003004507A1 (en) | A kind of oligosaccharides, their sulfates and dendrimers, and the uses of these compounds | |
| CN1066444C (en) | Nitrogenous derivs. of elemene and their use as anticancer drugs | |
| CN101225049B (en) | Beta-elemene amino acid derivatives as well as synthetic method and use thereof | |
| CN1978442A (en) | Synthesis method of (R, R, R, S)2,2' - [ imino-di (methylene) ] bis- (6-fluoro-3, 4-dihydro-2H-1-benzopyran-2-methanol) nepyrrolel hydrochloride | |
| CN100567243C (en) | Chalcone derivative and uses thereof | |
| CN1425658A (en) | Synthetic method for (S)-3-hydroxy-gamma-butyrolactone | |
| CN106957307B (en) | A kind of dantrolene sodium derivative and preparation method thereof | |
| CN106397433B (en) | Three pyridinium hydroxide of 2- (2- pyridine) -6- (the chloro- 3- trifluoromethylbenzoyl of 2-) -5,7,8- simultaneously [4,3-d] pyrimidine and preparation method thereof | |
| CN108440242A (en) | A kind of synthetic method of high activity chirality alkynol (S, E) -1,9- diene -4,6- diine -3- octadecyl alcolols | |
| CN114957340B (en) | Preparation method and application of binuclear iridium complex for inducing iron death | |
| CN112094278B (en) | Aurovertin B derivative and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |